MedTrace Logo

Response of the Myocardium to Hypertrophic Conditions in the Adult Population

NCT02670031 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2023-08-02

No results posted yet for this study

Summary

Hypertension and aortic stenosis are the two leading conditions that cause thickening of the heart muscles (left ventricular hypertrophy). Left ventricular hypertrophy is initially adaptive to maintain optimal heart function. Ultimately, heart failure occurs as a result of progressive muscle cell death and scarring (myocardial fibrosis). Dedicated techniques using cardiovascular magnetic resonance imaging (MRI) and novel high-sensitivity cardiac troponin blood assays are potential markers to detect myocardial fibrosis. Although hypertension-related heart disease is very common in Singapore, the significance of myocardial fibrosis is not well understood. In this study, the significance of myocardial fibrosis in 2000 patients with hypertension would be investigated. This will be the largest study using state-of-the-art MRI to examine the importance of myocardial fibrosis in hypertensive heart disease. 1000 participants, with at least 1 year follow-up, will be invited for a repeat assessment.

Conditions

  • Left Ventricular Hypertrophy
  • Hypertension
  • Myocardial Fibrosis

Interventions

OTHER

Cardiovascular Magnetic Resonance

For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.

OTHER

Echocardiogram

For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.

OTHER

Electrocardiogram

To examine specific function of the heart.

DEVICE

Ambulatory Blood Pressure Monitoring

A 24-hour test.

OTHER

Retinal Photography (Optional)

The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.

Sponsors & Collaborators

  • National Heart Centre Singapore

    lead OTHER

Principal Investigators

  • Calvin WL Chin, MBBS, PhD · National Heart Centre Singapore

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2031-09-30
Completion
2031-09-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02670031 on ClinicalTrials.gov